Nitan
42.8K posts
APRIL CONTEST leaderboard update 🟣📊
Only 2 weeks left to join, and $Ink is getting so loud that our initial 0.1 ETH prize estimate is already closer to 0.15 ETH based on current prices. By the time rewards are airdropped, the total value could be much higher.
There are 10 prizes in total:
- 5 for the top wallets on the leaderboard
- 5 given out by random draw, so everyone still has a shot 👀
To be eligible for either the leaderboard or the random draw, don’t forget to mint the NFT. Activate your multiplier boost by minting several ones to improve your chances.
Check the pinned post on our profile if you want in before April ends.
English
@KCEX_Official Crypto really held up here… didn’t expect gold to underperform this much. BTC outperforming in a crisis is a big signal. Do you think this trend sticks or is it just short-term rotation?
English
📊 Since the Middle East crisis (Mar 1 → Apr 15):
🟠 WTI Crude +27.4%
🔵 $ETH +15.26% 🔥
🟡 $BTC +8.03%
🟢 NASDAQ +4.76% | S&P +1.58%
⚪️ Dow -1.06%
💥 Gold -8.42% | Silver -8.95%
The “safe haven” narrative? Crypto held — gold didn’t.
$BTC outperformed every traditional hedge as Hormuz fears escalated.
#Bitcoin #Ethereum #Macro #SafeHaven #Gold
English
🚀 $ST perpetual futures are NOW LIVE on #KCEX! @sentioxyz
🔹 Leverage: 1-25x adjustable
🔗 Trade Now:👉 kcex.com/futures/exchan…
#KCEX #CryptoFutures #NewListing
English
Plz when you are done leave $HAMSTER for I want to buy it
Ahmed XM@ahmedxm01
I’m building an Estate called “Blockchain Estate. Each house will be uniquely identified using the names of popular crypto coins and tokens instead of traditional numbers. And when done you can only purchase with Crypto.
English
@BioProtocol @peptai_ This is actually kind of crazy.
Clear target, strong early signals, and only $500 to test it in the lab? If that holds up, this really changes how fast new drugs can get validated.
English
Drug-naive ADHD patients show measurably lower orexin-A/B levels.
OX2R is the receptor that drives arousal and attention. No approved drug activates it. Every orexin therapy on the market does the opposite.
@BioProtocol's scientific team and @peptai_ developed OX2R-004, a selective peptide agonist targeting exactly this gap, and ran it through the full 8-gate computational pipeline over 24 hours on @BioProtocol infrastructure.
It cleared most gates: Clean binding geometry, zero immunogenicity signals, toxicity score 0.0.
Two known failure points remain but both have standard peptide engineering fixes.
First wet-lab validation costs $500.
Traditional pharma spends years and tens of millions to reach this same checkpoint.
The modality is open, the biology is solid, and the barrier to entry just collapsed.
Paul Kohlhaas bio/acc@paulkhls
🧵 Over 24 hours, our scientific team and AI scientist infrastructure developed a novel peptide agonist to potentially treat ADHD. Below is our paper for a pre-IND computational feasibility assessment for OX2R-004: an 18-residue peptide agonist designed as a selective OX2R agonist for ADHD. Why this matters? No approved orexin agonists exist anywhere. All marketed orexin drugs are dual OX1R/OX2R antagonists for insomnia. Clinical-stage ones are small molecules for narcolepsy only. We did this with @peptai_ a novel full 8-gate computational pipeline in one shot developed by @BioProtocol community 👇
English
